A regulatory action has been taken against Cadila due to a name mix-up involving the acidity pill Aciloc. Mundhe's FDA has shut down three Cadila godowns as a result of this issue.

The specifics of the name mix-up and the circumstances surrounding the shutdown are not detailed here, but further information can be found through the source.

Details about the shutdown and its implications are available from the original report, which provides more context on the situation and the actions taken by Mundhe's FDA.